- Home
- SEE vs GH Comparison
SEE vs GH Comparison
Compare SEE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- GH
- Stock Information
- Founded
- SEE 1960
- GH 2011
- Country
- SEE United States
- GH United States
- Employees
- SEE N/A
- GH N/A
- Industry
- SEE Major Chemicals
- GH Medical Specialities
- Sector
- SEE Industrials
- GH Health Care
- Exchange
- SEE Nasdaq
- GH Nasdaq
- Market Cap
- SEE 4.6B
- GH 4.9B
- IPO Year
- SEE N/A
- GH 2018
- Fundamental
- Price
- SEE $33.66
- GH $54.79
- Analyst Decision
- SEE Strong Buy
- GH Strong Buy
- Analyst Count
- SEE 10
- GH 17
- Target Price
- SEE $38.80
- GH $58.24
- AVG Volume (30 Days)
- SEE 1.4M
- GH 2.3M
- Earning Date
- SEE 11-06-2025
- GH 11-05-2025
- Dividend Yield
- SEE 2.38%
- GH N/A
- EPS Growth
- SEE N/A
- GH N/A
- EPS
- SEE 1.98
- GH N/A
- Revenue
- SEE $5,325,400,000.00
- GH $828,849,000.00
- Revenue This Year
- SEE N/A
- GH $28.07
- Revenue Next Year
- SEE $1.94
- GH $21.61
- P/E Ratio
- SEE $17.04
- GH N/A
- Revenue Growth
- SEE N/A
- GH 28.74
- 52 Week Low
- SEE $22.78
- GH $20.14
- 52 Week High
- SEE $38.85
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- SEE 63.78
- GH 41.26
- Support Level
- SEE $32.66
- GH $53.67
- Resistance Level
- SEE $34.21
- GH $61.95
- Average True Range (ATR)
- SEE 0.71
- GH 2.29
- MACD
- SEE 0.13
- GH -1.51
- Stochastic Oscillator
- SEE 77.73
- GH 7.82
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.